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Objectives: To evaluate the effect of intensive lipid-lowering treatment on coronary artery calcification in a
substudy of a trial recruiting patients with calcific aortic stenosis.
Methods: In a double blind randomised controlled trial, 102 patients with calcific aortic stenosis and
coronary artery calcification were randomly assigned by the minimisation technique to atorvastatin 80 mg
daily or matched placebo. Coronary artery calcification was assessed annually by helical computed
tomography.
Results: 48 patients were randomly assigned to atorvastatin and 54 to placebo with a median follow up of
24 months (interquartile range 24–30). Baseline characteristics and coronary artery calcium scores were
similar in both groups. Atorvastatin reduced serum low density lipoprotein cholesterol (253%, p , 0.001)
and C reactive protein (249%, p , 0.001) concentrations whereas there was no change with placebo
(27% and 17%, p . 0.95 for both). The rate of change in coronary artery calcification was 26%/year
(0.234 (SE 0.037) log arbitrary units (AU)/year; n = 39) in the atorvastatin group and 18%/year (0.167
(SE 0.034) log AU/year; n = 49) in the placebo group, with a geometric mean difference of 7%/year
(95% confidence interval 23% to 18%, p = 0.18). Serum low density lipoprotein concentrations were not
correlated with the rate of progression of coronary calcification (r = 0.05, p = 0.62).
Conclusion: In contrast to previous observational studies, this randomised controlled trial has shown that,
despite reducing systemic inflammation and halving serum low density lipoprotein cholesterol
concentrations, statin treatment does not have a major effect on the rate of progression of coronary
artery calcification.
C
oronary artery calcification is an independent risk
factor for coronary heart disease, with even low
coronary calcium scores doubling the risk of coronary
events.1 The relative risk associated with coronary calcifica-
tion is greater than that associated with established factors
such as smoking, hypertension and diabetes mellitus.
Progression of coronary artery calcification is associated with
a higher incidence of coronary events even among people
who are asymptomatic at the time of initial scanning.2 Thus,
not only is the presence of coronary artery calcification
indicative of atheromatous plaque disease but its progression
may correspond with cardiovascular event rates.
Statin treatment has a proven role in the primary3 4 and
secondary prevention5–8 of cardiovascular disease, with
incremental benefits seen with more intensive reductions in
serum cholesterol concentrations.8 Previous studies9 10 have
reported that statins can halt the progression and may even
induce regression of coronary artery calcification. Indeed, the
rate of progression of coronary artery calcification correlates
with the average serum low density lipoprotein (LDL)
cholesterol concentration.9 This has led to the use of
computed tomography to monitor disease progression and
response to treatment, particularly with statins. Two recent
trials, however, did not show a benefit of statin on the
progression of coronary artery calcification in asymptomatic
people.11 12
The SALTIRE (Scottish Aortic Stenosis Lipid lowering
Therapy, Impact on Regression) trial was a prospective
double blind, randomised controlled study of intensive
lipid-lowering treatment of patients with calcific aortic
stenosis.13 As part of this trial, aortic valve and coronary
artery calcium scores are measured by helical computed
tomography. The objective of this substudy was to assess the
effect of atorvastatin 80 mg daily on the rate of progression of
coronary artery calcification in patients with calcific aortic
stenosis.
METHODS
Patient population
Patients aged . 18 years with calcific aortic stenosis (grade
1–3 calcification on echocardiography14) and a peak post-
valve velocity of > 2.5 m/s were recruited from eight hospital
centres across the southeast of Scotland. Exclusion criteria
were women of childbearing potential without contraception,
active or chronic liver disease, history of alcohol or drug
misuse, severe mitral stenosis (valve area , 1 cm2), severe
mitral or aortic regurgitation,15 major left ventricular dys-
function (ejection fraction , 35%), planned aortic valve
replacement, intolerance to statins, patients who were taking
or would in the opinion of the treating physician benefit from
statins, baseline serum total cholesterol of , 4.0 mmol/l, and
permanent pacemaker or cardiodefibrillator. For the sub-
study, we also excluded patients who had no coronary artery
calcification on computed tomography. The study was
conducted with the approval of all the regional research
ethics committees and in accordance with the Declaration of
Abbreviations: AU, arbitrary units; BELLES, Beyond Endorsed Lipid
Lowering with EBT Scanning; CRP, C reactive protein; LDL, low density
lipoprotein; SALTIRE, Scottish Aortic Stenosis Lipid Lowering Therapy,
Impact on Regression
1207
www.heartjnl.com
Helsinki. Written informed consent was obtained from each
participant.
Study protocol
Between March 2001 and April 2002, the blinded study
coordinator randomly assigned eligible patients by the
minimisation technique16 with a dedicated locked computer
program (Edinburgh University), which incorporated eight
baseline variables: age, sex, smoking habit, hypertension,
diabetes mellitus, serum cholesterol concentration, peak
aortic jet velocity and aortic calcium score. Patients were
assigned either to atorvastatin 80 mg daily or matched
placebo (Pfizer, Tadworth, UK) as a single daily dose in
numbered containers.
Patients were assessed at baseline, two months, six months
and every six months thereafter for a minimum of two years.
Clinical evaluation included assessment of functional status,
adverse events and biochemical blood analysis. Serum high
sensitivity C reactive protein (CRP) concentrations were
determined by a highly sensitive immunonephelometric
method (Dade Behring, Milton Keynes, UK) as previously
described.17 All patients underwent computed tomography
within the month before randomisation to study treatment
and at each annual visit. Randomly assigned patients who
were later treated with an open label statin by their attending
physician were immediately scanned and withdrawn from
further observation.
Computed tomography
A single blinded operator performed computed tomography
with a double helix scanner (Twin II Flash; Philips Medical
Systems (UK), Stevenage, UK) calibrated against a standard
phantom. Images were acquired in 2.7 mm slices (with a
0.75 s full 360˚ scan mode) through the region of the
coronary arteries with a pitch of 0.7 and an increment of
1.3 mm during held inspiration. Exposure factors were
120 kV at 270 mA and the scan angle was 360 .˚ Images were
analysed off line with an automated, computerised software
program (Picker cardiac scoring). This uses an Agatston
scoring method,18 producing sensitivity and specificity com-
parable with electron beam computed tomography.17 Scans
were scored by both the Agatston (130 HU threshold) and
the modified Agatston (90 HU threshold) methods.19 The
Agatston method has been shown to reduce interobserver
and interscan variation compared with the threshold of
90 HU.20 To assess the reproducibility of the method, repeated
baseline computed tomography scans were recorded within
four weeks of each other in an unselected random sample of
16 patients.
Data analysis and statistics
Coronary artery calcium scores are expressed in arbitrary
units (AU) based on the 130 HU threshold. The calcium
scores and high sensitivity CRP concentrations were not
normally distributed and data are presented as median
455 Eligible
patients identified
16 Met exclusion criteria
at baseline assessment
13 Discontinued study medication
      before first annual visit:
Death
Non-fatal adverse event
Drug side effects
Patient preference
1
1
6
5
1 Continued off study drug (ITT)
155 Randomised
77 Assigned atorvastatin 78 Assigned placebo
39 CT datasets 49 CT datasets
284 Declined to participate
65 for clinical
end point analysis (ITT)
70 for clinical
end point analysis (ITT)
10 Discontinued study medication
      before first annual visit:
Death
Aortic valve replacement
Drug side effects
Patient preference
Statin introduced
1
1
3
4
1
2 Continued off study drug (ITT)
17 No coronary artery
      calcification
16 No coronary artery
     calcification
9 No follow-up scan 5 No follow-up scan
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patients recruited into the trial and substudy. CT, computed
tomography; ITT, intention to treat.
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(interquartile range) or mean (SD) after logarithmic trans-
formation (log AU). The primary end point, the rate of
change of coronary calcium scores, was analysed with
random coefficient models13 21 after logarithmic transforma-
tion of the scores. In summarising the data, we calculated the
change in coronary artery calcium scores by dividing the
change between the baseline and final scores by the duration
of follow up. Rate of change in coronary calcium score is
expressed as percentage change per year or as absolute
change in the logarithm of the coronary artery calcium score.
Reproducibility was assessed by the method of Bland and
Altman.21 As well as tests of significance, 95% confidence
intervals are reported as appropriate. Significance was taken
as a two-sided p , 0.05.
RESULTS
Of 155 patients recruited into the SALTIRE trial, 102 had
coronary calcification at baseline (fig 1), of whom 88 had at
least two scans. Coronary calcification predominated in the
left anterior descending artery (100% of patients) although it
was also present in the circumflex (33%) and right (27%)
coronary arteries. Baseline characteristics and coronary artery
calcium scores were well matched in both treatment groups
(table 1) in the 88 evaluable participants.
Reproducibil ity
The reproducibility of the left anterior descending coronary
score and of the total coronary score was examined with the
approach of Bland and Altman.21 Without transformation,
the difference between replicate observations tended to
increase with the magnitude of the measurement. After
logarithmic transformation, higher values showed stable
differences, but differences were higher at the lowest scores.
Overall, the differences on the log scale correspond to a
coefficient of variation of 28% for both variables, but when
the analysis was restricted to the 10 pairs with a geometric
mean score above 100, the coefficient of variation was 10%
for both variables.
Table 1 Baseline characteristics of participants with
calcific aortic stenosis in the treatment groups
Characteristic
Atorvastatin
(n = 39)
Placebo
(n = 49)
Age (years) 70 (8) 70 (9)
Men 74% 78%
Body mass index (kg/m2) 29 (5) 28 (5)
Cardiovascular risk factors
Hypertension 22 28
Hyperlipidaemia 3 2
Diabetes mellitus 0 2
Current smoker 5 10
Cardiovascular disease
Coronary heart disease 7 13
Cerebrovascular disease 5 7
Peripheral vascular disease 3 7
Drug history
Aspirin 17 26
ACE inhibitor 7 8
b blocker 11 15
Warfarin 4 8
Blood pressure (mm Hg)
Systolic 143 (18) 140 (19)
Diastolic 82 (11) 78 (11)
Lipid profile
Total cholesterol (mmol/l) 5.7 (0.9) 5.5 (0.9)
LDL cholesterol (mmol/l) 3.6 (0.8) 3.4 (0.7)
HDL cholesterol (mmol/l) 1.5 (0.4) 1.5 (0.4)
Total cholesterol:HDL 4.2 (1.2) 4.0 (1.0)
Triglycerides (mmol/l) 1.5 (0.8) 1.4 (0.7)
Coronary calcification score (AU)
Left anterior descending artery 112 (40–285) 207 (76–461)
Circumflex artery 0 (0–9) 0 (0–4)
Right coronary artery 0 (0–29) 0 (0–0)
Total coronary score 195 (57–448) 235 (83–526)
Log total coronary score (log AU) 2.16 (0.68) 2.30 (0.65)
Continuous variables stated as mean (SD) or median (interquartile
range).
ACE, angiotensin-converting enzyme; AU, arbitrary unit; HDL, high
density lipoprotein; LDL, low density lipoprotein.
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Figure 2 Progression of (A) coronary artery calcification, (B) serum C
reactive protein (CRP) concentrations (p , 0.001, atorvastatin v
placebo) and (C) serum low density lipoprotein (LDL) cholesterol
concentrations (p , 0.001, atorvastatin v placebo) in patients treated
with atorvastatin 80 mg daily or matched placebo. AU, arbitrary units.
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Figure 3 Absolute rate of change in coronary calcium score expressed
in arbitrary units (AU) per year for patients treated with atorvastatin 80
mg or matched placebo.
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Effect of atorvastatin treatment
Patients were followed up for a median of 24 months
(interquartile range 24–30). Atorvastatin 80 mg daily more
than halved serum LDL cholesterol concentrations (53 (SD
19)%, p , 0.001), whereas placebo had no effect (fig 2). This
reduction in serum LDL cholesterol concentrations was
associated with a major decrease in serum CRP concentra-
tions from 1.95 (interquartile range 1.15–4.86) to 1.00 mg/l
(0.49–2.31) (Wilcoxon signed rank test p , 0.001) (fig 2).
Atorvastatin was well tolerated: two patients in the placebo
group and five patients in the atorvastatin group discon-
tinued the treatment, predominantly as a result of gastro-
intestinal upset. One patient taking atorvastatin had an
increase in creatine kinase of . 5 times the upper limit of
normal without symptoms of myositis and was withdrawn at
the request of the Data Monitoring Committee. There were
no cases of rhabdomyolysis.
Coronary artery calcium score
Atorvastatin did not affect the rate of progression of the
coronary artery calcium score (fig 2). Similar results were
obtained when the 90 HU threshold was used (42 (SD 73)%/
year in the atorvastatin group and 29 (SD 37)%/year in the
placebo group, p = 0.24). Serum LDL cholesterol concentra-
tions did not correlate with the rate of progression of
coronary artery calcification (r = 0.05, p = 0.62).
The rates of change of coronary artery calcium scores were
primarily analysed on the logarithms of the scores by random
coefficients models.22 This showed no difference between the
average rates of change in the two treatment arms
(p = 0.18). The mean coronary calcium score increased by
0.234 (SE 0.037) log AU/year in the atorvastatin group and
0.167 (SE 0.034) log AU/year in the placebo group. These
figures correspond to a 26%/year increase in the atorvastatin
group and 18%/year in the placebo group. The geometric
mean (adjusted for baseline) is 7% higher at one year with
atorvastatin than with placebo, with 95% confidence limits
ranging from 3% lower to 18% higher. Figure 3 summarises
the observed annual changes in coronary calcium scores,
calculated from the first to the last visit.
As anticipated in such a modest clinical trial, all cause
mortality, cardiovascular mortality or cardiovascular hospi-
talisation did not differ significantly between the two groups.
DISCUSSION
We have confirmed that, despite major reductions in serum
LDL cholesterol and CRP concentrations, atorvastatin 80 mg
daily did not halt the progression, or induce regression, of
coronary artery calcification in patients with calcific aortic
stenosis. Consistent with recent trials of asymptomatic
people,11 12 our findings contrast notably with previous
observational studies and suggest that the potential bene-
ficial effects on coronary artery calcification have been
overestimated.
Previous observational and non-randomised prospective
studies9 10 have suggested that reductions in serum LDL
cholesterol concentrations decrease the progression of cor-
onary calcification. Not all observational studies, however,
have had consistent findings. In the largest observational
study of 182 patients, Hecht and colleagues23 recently found
no difference in the progression of coronary calcium scores in
patients who were maintained on lipid-lowering treatment
and achieved significant reductions in serum LDL cholesterol
concentrations. Observational data may be misleading and
prospective randomised controlled trials are necessary to
confirm or to refute these interesting preliminary observa-
tions. The recent BELLES (Beyond Endorsed Lipid Lowering
with EBT Scanning) trial12 found no differential effect
between pravastatin (40 mg daily) and atorvastatin (80 mg
daily) on the progression of coronary artery calcification in
615 hyperlipidaemic postmenopausal women. Study follow
up was brief (one year), however, and there was no placebo
control group. The St Francis Heart Study11 randomly
assigned 1005 asymptomatic middle-aged men and women
with high coronary artery calcium scores to combination
atorvastatin 20 mg, vitamin C 1 g, and vitamin E (a
tocopherol) 1000 U daily or to matching placebos. After 4.3
years of follow up, the rate of progression of coronary artery
calcification did not differ.
We have conducted a double blind randomised controlled
trial with helical computed tomography in patients with
aortic stenosis. Minimisation technique ensured good match-
ing of the baseline characteristics of the patient population
and reproducibility studies confirmed the validity of our
repeated assessments. Although documenting very similar
rates of progression of coronary calcification to previous
studies,9 10 23 we have not observed a reduction in coronary
calcification with intensive lipid-lowering treatment despite
more than halving serum LDL cholesterol concentrations.
Statins have been extremely successful in the primary and
secondary prevention of cardiovascular disease. Why then
have we and others not observed a beneficial effect of statin
on coronary artery calcification? Unstable atherosclerotic
plaques have a large lipid-rich core, a preponderance of
macrophages and foam cells, and a thin fibrous cap contain-
ing few smooth muscle cells.24 It has been suggested that
calcified lesions may be relatively more stable,25 indicating a
possible protective role of calcification in coronary plaques.
Statins produce many of their beneficial effects through
plaque stabilisation. In both primate26 and swine27 models,
antiatherosclerotic interventions are associated with an
increase in vascular fibrous tissue and calcification. This
calcium deposition continues during the initial phase of
plaque regression due to the death of foam cells and an
increase in necrotic tissue. Thus, vascular calcification may
have a role in the initial stabilisation of atherosclerotic
plaques. This is consistent with our findings and would
account for the lack of effect on the progression of coronary
artery calcification despite a reduction in serum CRP
concentrations.
After the initial stabilisation of the atherosclerotic plaque,
subsequent progression of coronary calcification would be
anticipated to be inhibited. The present study was brief, and
follow up was only continued for a median of two years. It
would be important to extend our observations to five or
more years to assess properly the impact of statin on the
long-term progression of coronary artery calcification. It
should be acknowledged, however, that the clinical benefits
of statin are apparent within the first few years,6–8 and in
some cases the first few months,28 of treatment. Moreover,
the St Francis Heart Study showed no beneficial effects
despite 4.3 years of follow up.9
On the basis of previous non-randomised studies,10 the
practice of performing serial computed tomography to
monitor disease progression and the response to treatment
has become widespread, especially in North America. Our
data, and those of the St Francis Heart Study11 and the
BELLES study,12 indicate that repeated scanning to assess
response to statin is not justified. Indeed, the radiation dose
incurred for such serial scans poses potential health risks,
particularly when multidetector computed tomography scan-
ners are used.
Study limitations
Several factors should be taken into account when consider-
ing the results of our study. This was a substudy of the
SALTIRE trial13 that recruited only patients with calcific aortic
stenosis. Our findings are consistent, however, with two
1210 Houslay, Cowell, Prescott, et al
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recent randomised controlled trials in asymptomatic younger
people without valvular heart disease.11 12 Our study therefore
suggests that failure of statins to restrict the progression of
coronary artery calcification can be extended to include
patients with valvular heart disease as well as older
populations. Moreover, our findings suggest that the lack of
benefit seen in the St Francis Heart Study is not attributable
to the modifying effects of antioxidant vitamins.
When compared with electron beam computed tomogra-
phy, the accuracy of helical computed tomography in
detecting coronary artery calcification has been ques-
tioned.18 29 Technological advances have also meant that
double helical scanners have now been overtaken by 64-slice
scanners. At trial inception, the double helix scanner was the
latest technology, and it would have been inappropriate to
replace the scanner during the conduct of the trial. Moreover,
our approach has been previously validated21 and we have
shown good reproducibility of coronary artery calcification
scores in patients with scores of . 100 AU. We do not believe
the absence of a major beneficial effect on coronary artery
calcification is attributable to our methods. We acknowledge
that our population size is modest; however, the 95%
confidence intervals can exclude a relative reduction in
progression of coronary artery calcification of . 3%/year. We
therefore suggest that if lipid-lowering treatment does reduce
the progression of coronary artery calcification then the effect
is rather small.
The method of quantification of coronary artery calcifica-
tion is controversial. The Agatston method is traditionally
used but this may overestimate the coronary calcium score in
newer generation scanners with reduced slice thickness due
to partial voluming. More recent methods include the
volume30 and the coronary calcium mass31 scores, although
neither is superior to the Agatston score in terms of
reproducibility from consecutive scans in an individual
patient.32
Conclusion
We conclude that intensive lipid-lowering treatment does not
halt the progression, or induce regression, of coronary artery
calcification. Although coronary artery calcium scores corre-
late well with the presence of atherosclerosis and predict
future coronary risk, our findings confirm that monitoring
progression of coronary artery calcification to assess the
response to lipid-lowering treatment has no role.
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Anomalous origin of right coronary artery from the mid left anterior descending coronary artery
A
59-year-old women underwent
diagnostic coronary angiography
with a history of atypical chest
pain and an inconclusive treadmill
exercise tolerance test. Cine-angiogram
revealed an unusual origin of the right
coronary artery (RCA) arising from the
mid left anterior descending coronary
(LAD) artery and coursing to the right,
anterior to the right ventricular outflow
tract. Such an anomaly is unusual and
has not been listed in the classification
of such anomalies.
Coronary anomalies are seen in about
1% of cineangiograms. While some
anomalies have been associated with
adverse clinical outcomes, most are
benign. The RCA has been documented
to have an anomalous origin from
the left anterior coronary sinus and
pulmonary trunk, but the origin of the
RCA from the LAD has not been
reported before.
P Saravanan, P Mennim, J E Hancock
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Huge left atrial thrombus in a patient with mitral bioprosthesis
A
77-year-old woman had suffered
from atrial fibrillation and rheu-
matic mitral stenosis for more
than 20 years. She underwent mitral
valve replacement with bioprosthesis six
months before her admission.
Inadequate anticoagulation treatment
was noted during the follow-up period.
She presented with unsteady gait and
dizziness to our emergency room. Brain
magnetic resonance images confirmed
cerebellar infarction. Echocardiography
was arranged to search for the possible
embolus source, and revealed a huge left
atrial thrombus. Because of the thrombus
burden and recent stroke, redo cardiac
surgery was proposed three weeks after
the cerebrovascular event. The preopera-
tive computed tomography (CT) for redo
surgery found a large left atrial mass (left
panel). During the less invasive cardiac
surgery via right small thoracotomy,
transoesophageal echocardiography
revealed the significant thrombus burden
again (right panel). The bioprosthesis
was found to be functioning well and
thrombus-free. Additional left atrial
appendage closure and endocardial
ablation were performed to reduce the
risk of future thromboembolism.
K-M Chiu, T-Y Lin, S-H Chu
kmchius@yahoo.com.tw
Computed tomography demonstrating a huge
mass in an enlarged left atrium. LA, left atrium;
LV, left ventricle; T, thrombus.
Transoesophageal echocardiography revealing
a heavy thrombus burden in the posterior wall
of left atrium with the bioprosthesis in the mitral
position (M).
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